SCHEMBL9301157

SCHEMBL9301157

Cc1cc(S)n2nccc2n1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 3/20 0.43
UBE2M P61081 1/20 0.39
DCUN1D1 Q96GG9 1/20 0.39
PDE2A O00408 2/20 0.37
KCNN3 Q9UGI6 3/20 0.35
PIK3CG P48736 1/20 0.34
KDM4E B2RXH2 2/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CCNT1 O60563 4/20 0.33
CDK9 P50750 4/20 0.33
CRHR1 P34998 2/20 0.33
S100A4 P26447 1/20 0.33
RAD52 P43351 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3460690 0.80 PIK3CG (0.48) PDE10AUBE2MDCUN1D1PDE2APIK3CG
SCHEMBL22932762 0.78 MEN1 (0.43) PDE10AUBE2MDCUN1D1PDE2AKCNN3
SCHEMBL4431791 0.77 ALDH1A1 (0.50) PDE10AUBE2MDCUN1D1PDE2APIK3CG
SCHEMBL659433 0.77 PDE10A (0.67) PDE10AUBE2MDCUN1D1PDE2AKCNN3
SCHEMBL4102510 0.77 PDE10A (0.43) PDE10AUBE2MDCUN1D1PDE2AKCNN3
SCHEMBL20406305 0.77 PDE10A (0.43) PDE10AUBE2MDCUN1D1PDE2AKCNN3
SCHEMBL10408224 0.77 PDE10A (0.43) PDE10AUBE2MDCUN1D1PDE2AKCNN3
SCHEMBL7438434 0.77 PRKAB2 (0.48) PDE10AKCNN3CCNT1CDK9CRHR1
SCHEMBL13769278 0.74 PDE2A (0.46) PDE10APDE2AKCNN3CCNT1CDK9
SCHEMBL21212282 0.74 PDE2A (0.41) PDE10AUBE2MDCUN1D1PDE2AKCNN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 WO disclosed
EP-3078662-A1 PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS Array Biopharma, Inc. (US) 2016-10-12 EP disclosed
EP-2727910-B1 Pyridin-2-yl-thiourea and Pyridin-2-yl-amine derivatives as intermediates for the preparation of Pyridin-2yl-amino-1,2,4-thiadiazole glucokinase activators ARRAY BIOPHARMA INC (US) 2016-03-16 EP disclosed
EP-2727910-A1 Pyridin-2-yl-thiourea and Pyridin-2-yl-amine derivatives as intermediates for the preparation of Pyridin-2yl-amino-1,2,4-thiadiazole glucokinase activators Array Biopharma, Inc. (US) 2014-05-07 EP disclosed
US-5319140-A Antibiotics HOFFMANN-LA ROCHE INC. (US) 1994-06-07 US disclosed
US-5138066-A Intermediates for cephalosporins with sulfur-containing oxyimino side chain HOFFMANN-LA ROCHE, INC. (US) 1992-08-11 US disclosed
US-5073550-A Bactericides HOFFMANN-LA ROCHE INC. (US) 1991-12-17 US disclosed
US-5036064-A Antibiotics HOFFMANN-LA ROCHE INC. (US) 1991-07-30 US disclosed
US-4966900-A FOR MICROBISM THERAPY, BACTERIAL INFECTIONS SANKEI PHARMACEUTICAL COMPANY LTD. (JP) 1990-10-30 US disclosed
EP-0303172-A2 Oxyimino-cephalosporins F. HOFFMANN-LA ROCHE AG (CH) 1989-02-15 EP disclosed
EP-0254495-A2 Beta-Lactam compound, method for preparing the same, medicinal composition for bacterially infectious disease therapy containing the same and intermediates for synthesis of the same SANKEI PHARMACEUTICAL COMPANY LIMITED (JP) 1988-01-27 EP disclosed